Navigation Links
Pharsight Achieves $7.4 Million in Quarterly Revenue
Date:1/24/2008

ities available to us with the successes we have achieved during the first nine months of fiscal 2008," said Will Frederick, senior vice president and chief financial officer. "During the fiscal third quarter, we successfully re-listed our common stock on the Nasdaq Capital Market, achieving a key goal that we outlined for our investors in fiscal 2007 to heighten our opportunities within the overall investment community. This quarter we also achieved positive fiscal year-to-date cash flow with cash, cash equivalents and short-term investments now in excess of $15 million, with no outstanding debt and a $5 million available credit facility. With our growing portfolio of products and consulting services, and the continued commitment from our dedicated employees, our top- and bottom- line results remain on track with our stated annual guidance."

While Pharsight expects that over the long-term revenues and gross margin will increase in response to customer demand, revenue and gross margin in individual quarters may fluctuate in the future for its software business based upon timing of completion of large software installations. In addition, quarterly revenue and gross margin may also be impacted by the Company's consulting businesses based upon timing of completion of milestones for fixed fee contracts and related revenue recognition for these activities.

Conference Call

Pharsight management will host a conference call and webcast tomorrow, January 25, 2008 at 10:00 a.m. Pacific Time to discuss the Company's fiscal third quarter 2008 results, outlook for fiscal 2008 and current corporate developments. The dial-in number for the conference call is 800-240-2134 for domestic participants and 303-262-2130 for international participants. To access the live webcast of the call, go to Pharsight's website at http://www.pharsight.com and click on the About Pharsight icon. The webcast can then be accessed u
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
2. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
3. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
4. Pharsight Announces 1-For-3 Reverse Stock Split
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
7. Pharsight Hosts Fourth Annual PKS User Group Meeting
8. Pharsight Expands Strategic Consulting Services Team
9. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
10. Pharsight Achieves First License Sale for Public-Source Database
11. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research Report ... "2014 Deep Research Report on Global and China ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... and China Acetic Acid Industry" is a professional ... and Global Acetic Acid Market. The ...
(Date:9/18/2014)...  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... and metabolic processes, is pleased to announce the addition of ... Nola E. Masterson , a California ... September 17, 2014. "We,re very pleased and ... states Andrew Dahl , President and CEO. "She joins ...
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 ... Chancellor John Sharp, Texas A&M Health Science Center ... U.S. Department of Health and Human Services (HHS), ... dedicated a national pandemic influenza vaccine manufacturing facility ... as an anchor for the Texas A&M Biocorridor ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Mass., March 11 Pressure,BioSciences, Inc. (Nasdaq: ... has joined PBI,s senior executive management team as ... nearly twenty years of experience in,sales and sales ... companies.,Mr. Potter will oversee PBI,s seven US-based, regional ...
... Lack of Flulike Side-Effects Drives Physician Prescribing of Copaxone over ... ... Resources, WALTHAM, Mass., ... advisory firms focusing on pharmaceutical and,healthcare issues, finds that Teva Pharmaceutical,s ...
... Inc.,(Nasdaq: RDEA ) today announced that Barry ... will present at Cowen and Company,s 28th Annual,Health ... Time: 4:40 p.m. Eastern Time, Location: ... Webcast:, http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=RDEA&item_id=1 ,779991, About ...
Cached Biology Technology:Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 2Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 3Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 4Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3Ardea to Present at Cowen and Company's 28th Annual Health Care Conference 2
(Date:9/18/2014)... Bulletin study uses tree rings to document arroyo ... in northern New Mexico, USA. By determining burial dates ... were able to precisely date arroyo sedimentary beds 30 ... with aerial imagery, LiDAR, longitudinal profiles, and repeat surveys ... are deep, oversized channels that have vertical or steeply ...
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
(Date:9/18/2014)... DNA, tiny strands of nucleic acid that contain instructions ... genetic data, our DNA is copied into RNA molecules, ... tasks in our cells. , Several years ago, ... all other known RNAs, this molecule is circular, and ... little has been known about how they are produced. ...
Breaking Biology News(10 mins):Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... largest mass extinction in the history of animal life occurred ... percent of marine species and 70 percent of life on ... the Earth. Multiple theories have aimed to explain the cause ... asteroid impact, massive volcanic eruptions, or a cataclysmic cascade of ...
... from Massachusetts Eye and Ear, Harvard Medical School, and ... system-on-chip (SoC) that could make possible a fully implanted ... 11at the IEEE International Solid State Circuits Conference in ... that electronically stimulates the auditory nerve to restore hearing ...
... patients who required care at Duke University Hospital during this ... vaccinated had severe cases and needed the most intensive treatment. ... treated for flu at the academic medical center from November ... only two of the 22 patients who required intensive care ...
Cached Biology News:Giant mass extinction may have been quicker than previously thought 2Giant mass extinction may have been quicker than previously thought 3Design prototype chip makes possible a fully implantable cochlear implant 2Young, unvaccinated adults account for severest flu cases 2
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... U.S. sourced, ideal for those ... Low hemoglobin; Endotoxin: < 1.0 ... US origin; U.S. sourced, ideal ... uncompromising quality. Low hemoglobin Endotoxin: ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
Biology Products: